< Back to news
FrieslandCampina introduces Vivinal® GOS Omni Syrup
Vivinal® GOS Omni: dairy power for improved gut health
Vivinal® GOS is the most widely used prebiotic* ingredient in infant nutrition worldwide. Since its introduction in 2000, 160 million babies were nourished with products containing Vivinal® GOS. In addition to leveraging the positive health effects of Vivinal® GOS for infants, FrieslandCampina is launching Vivinal® GOS Omni Syrup for a wider group of consumers.
The positive effects of Vivinal® GOS have been shown in various scientific studies in adults1,5,6 as well. The human intestine contains about 300-500 different species of bacteria7. These can be divided into health-promoting bacteria8, like Bifidobacteria and Lactobacilli, and harmful bacteria like certain Clostridia or E. coli. Vivinal® GOS Omni Syrup has been shown to stimulate the growth of the body’s own beneficial bacteria in the intestines1-3, which could result in several health-related effects, e.g. improved bowel function4-6 and better absorption of calcium and iron9,10. When GOS is used as a sugar replacement in end products it induces a lower blood glucose rise after consumption compared to sugar-containing products11.
Alongside the potential health effects of Vivinal® GOS Omni Syrup, it provides several application benefits for end products. It can be added at all process stages due to its high heat and acid stability, as well as easy solubility and outstanding sensorial properties. And Vivinal® GOS Omni is more suitable for processing at ultrahigh temperatures than, for instance, fructo-oligosaccharides (FOS).
These product properties provide excellent possibilities for the use of Vivinal® GOS Omni in various food applications such as beverages, milk drinks, cereals, confectionary as well as in dietary supplements (also in combination with probiotics) and performance nutrition.
Vivinal® GOS Omni Syrup will be officially launched at the Vitafoods exhibition in Geneva, Switzerland from 15-17 May.
- Walton, G. E. et al. J. Nutr. 107, 1466–75 (2012).
- Fanaro, S. et al. Pediatr. Gastroenterol. Nutr. 48, 82–8 (2009).
- Ben, X.-M. et al. Med. J. (Engl). 117, 927–931 (2004).
- Sierra, C. et al. Eur. J. Nutr. 54, 89–99 (2014).
- Sairanen, U. et al. Eur. J. Clin. Nutr. 61, 1423–8 (2007).
- Teuri, U. & Korpela, R. Ann. Nutr. Metab. 42, 319–27 (1998).
- Guarner, F, & Malagelada, J. R. Lancet. 361(9356), 512–519 (2003).
- Gibson, G. R. et al. Nat Rev Gastroenterol Hepatol. 14(8), 491-502 (2017).
- Whisner, C. M. et al. Br. J. Nutr. 110, 1292–303 (2013).
- Paganini, D. et al. Am. J. Clin. Nutr. 106, 1020–1031 (2017).
- EU. Commission Implementing Regulation (EU) 2016/854. Off. J. Eur. Union L 142/ 5-9 (2016).